Page results
-
In a major study involving UCLH a third of people who took a new drug for treating obesity lost more than one-fifth of their total body weight.
-
This page has been written for patients who are having radioactive iodine (131I) ablation and/or radioiodine treatment for thyroid cancer.
-
Our Getting Ready for Transition (GReaT) to secondary school parent information session will run on Tuesday 31 January 2023.
-
The world’s first COVID-19 vaccine study researching alternating doses and intervals of approved vaccines is taking place at UCLH.
-
This information aims to help answer some of the questions that you may have about having a robotic bilateral salpingo-oophorectomy (removal of tubes and ovaries).
-
The aim of this page is to provide you with information about flow-diverting stents and how they are used to treat cerebral (brain) aneurysms.
-
Every five years, a national Peer Review process casts a supportive but critical eye over red cell services across the UK.
-
This page aims to give you information about a way doctors can treat patients who have pancreatic collections or pseudocysts related to pancreatitis (inflammation of the pancreas).
-
In a joint public appearance, the trio, who are Honorary Patrons of Teenage Cancer Trust, visited the ward to meet young patients and thank staff for their work.
-
UCLH has recruited the first European participant to a trial looking at treating non-hospitalised Covid-19 patients with the drug remdesivir.
File results
-
FOI2017266 Viscosupplementation injections
-
FOI2017263 Self-administration of medicines policies and carers policies
-
FOI2017295 A&E attendances for acopia
-
FOI2017296 Contracts for the redevelopment of the Middlesex annexe and Royal London Hospital for Integrated Medicine
-
FOI2017307 Televisions for patients
-
FOI2017314 Deep brain stimulation procedures
-
FOI2017300 Sustainability and transformation
-
FOI2017315 Expenditure on reconciliation and validation of incomplete and missing RTT codes
-
FOI2017320 Patients with Multiple Sclerosis treated with MS disease modifying drugs
-
FOI/2023/0226 - Treatment with Nivolumab